By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
As Western heat wave ends, scientists try to make sense of its length and intensity - 2Banks for High Fixed Store Rates: Augment Your Investment funds
- 3From School Dropout to Example of overcoming adversity: My Excursion
- 4Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
- 5ABC News' Sam Champion opens up about recent health scare
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- U.S. overhauls childhood vaccine schedule, recommends fewer shots
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- Two Israeli infants among wounded by shrapnel in overnight Iranian missile barrage
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Fossils unearthed in Morocco are first from little-understood period of human evolution
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
